PTPN1 and obesity due to melanocortin 4 receptor deficiency: Hence, the final objective of this study is to propose potentially suitable animal models for in vivo drug testing and strategies for further rational inhibitor designs against PTP1B, particularly as treatment for obesity-associated diabetes.